Project description:Primary human bone marrow-derived mesenchymal stem cells (MSCs) were treated with recombinant human TGFb1 (10ng/ml) for different time points (1, 3, 7, 14, 24 hours)
Project description:Primary human bone marrow-derived mesenchymal stem cells (MSCs) were treated with recombinant human TNFa (50ng/ml) for different time points (1, 3, 7, 14, 24 hours)
Project description:LncRNA transcriptional profiling of human bone marrow-derived mesenchymal stem cells comparing control undifferentiated MSCs with Day 0 and Day 10 osteogenic differentiation stages
Project description:MicroRNA has the potential for cross-regulation and functional integration of discrete biological processes during complex physiological events. In this study, we found that the highly expressed microRNAs in exosomes from bone marrow derived macrophage appear to control fibrotic healing response in the tendon. Notably, fibrotic microRNA-21 in mice distributed in the early stage of healing after tendon injury, having the similar expression with mammals. Therefore, we hypothesized the bone marrow derived macrophage secreted miRNAs-containing exosomes play important functions in peritendinous adhesion after tendon injury.
Project description:Methylation data for MDS bone marrow derived MSCs before and after 5-Azacitidine treatment. Methylation profiles were measured using the Infinium Human MethylationEPIC BeadChip (Illumina). There are 5 healthy MSC and 8 high-risk MDS-MSC samples, untreated and treated with 5-Azacitidine in vitro.
Project description:Early osteoinductive bone marrow MSCs (e-MSCs) acquire enhanced hematopoiesis-supportive ability. We performed microarray analysis on e-MSCs. Cell chemotaxis-assosiated genes were positively enriched and cell adhesion-associated genes were negatively enriched compared with control MSCs. The expression of CXCL12 and VCAM1 extremely decreased.
Project description:The objectives of this study were to assess differences in Bone Marrow Derived Menenchymal Stromal Cells (MSCs) during co-culture with myeloma cells, and to assess differences in myeloma patient MSCs compared to normal donor MSCs. In the study presented here, a Bone Marrow Derived Menenchymal Stromal Cells (MSCs) were analyzed after FACS sorting from 2 week culture in osteogenic media lacking dexamethasone in 3D silk scaffold matrices either in co-culture with the multiple myeloma cell line GFP+Luc+MM1.S or Alone, as controls. Also, monocultures of MSCs grown in 2D, in MSC expansion media, from Normal Donor Controls (ND) or Multiple myeloma patients (MM) were analyzed. Analysis was done looking at microRNA expression in samples with the nanoString microRNA platform for 800 microRNAs.
Project description:Human mesenchymal stromal cells (MSCs) used in cell therapy are frequently administered directly out of thaw, yet the single-cell transcriptomic landscape of out-of-thaw MSC products is poorly defined. Here, cryopreserved bone marrow-derived MSCs from six healthy donors (seven lots) were characterized immediately after thawing using droplet-based single-cell RNA-sequencing on the Illumina-Bio-Rad ddSEQ platform. After SureCell-based UMI counting and knee filtering, profiles were analyzed with SC3 and Seurat. Donor-level clusters were identified that differ in immune-signaling, cell-surface, cell-cycle and metabolic gene programs, with low within-sample heterogeneity; cell-cycle status emerged as a major axis of inter-donor variation. Only the bone marrow samples are included in this submission.